As a physician in UBMD Nephrology, I see patients in outpatient and inpatient settings at the Erie County Medical Center (ECMC) both in nephrology consultation services as well as in medicine nephrology. I care for patients with a broad range of renal issues, including glomerular disorders, resistant hypertension, electrolyte disorders, polycystic kidney disease (PKD), acute kidney injury, chronic kidney disease (CKD) in all stages and end-stage renal disease (ESRD). As medical director of one of the satellite dialysis centers located at the Wende Correctional Facility, I am involved in all aspects of patient care and safety. My responsibilities include writing and revising dialysis protocols and monitoring and supervising the work of health care professionals involved in caring for these dialysis patients.
My clinical research focuses on diabetic nephropathy (diabetic kidney disease), which is the leading cause of CKD worldwide. Endothelin receptor antagonism (ERA) is one of the mechanisms being studied for prevention of diabetic nephropathy, and I am the principal investigator of SONAR, the Study Of Diabetic Nephropathy With Atrasentan. The purpose of this study is to assess the effects of the investigational ERA compound atrasentan on renal outcomes in patients with Type 2 diabetic nephropathy. The study will also evaluate atrasentan’s impact on quality of life in these patients. My responsibilities include recruiting eligible patients and caring for them while they are enrolled in the study. It is through this research that I want to accomplish my goal of finding the best possible treatment solution for my patients coping with diabetic nephropathy.
Our program is one of the major renal/pancreas transplant centers in the region; hence, my colleagues and I conduct research in many aspects of renal transplantation. As one example, we are interested in the influence of gender and race on pharmacokinetics of various immunosuppressive agents in African American and Caucasian renal transplant recipients. In research supported by the National Institutes of Health (NIH), the University at Buffalo and various pharmaceutical companies, we have helped define the differences that exist between male and female, and between white and black patients in regard to the metabolism of immunosuppressive medications. The differences we have defined benefit our patients: we can identify the best treatment protocol for each individual patient we care for.
I teach medical students during their nephrology electives. I also teach medical residents during their clinical rotations in nephrology, and I teach and supervise nephrology fellows.
Fluent Hindi, Fluent Arabic
This UBMD clinician teaches at the University at Buffalo's School of Medicine and Biomedical Sciences. Learn more about this clinician’s research and teaching activities. View credentials, publications, professional involvement and more.